

## ORIGINAL ARTICLE

# Endotoxin in concentrated coarse and fine ambient particles induces acute systemic inflammation in controlled human exposures

Behrooz Behbod,<sup>1</sup> Bruce Urch,<sup>2,5</sup> Mary Speck,<sup>2</sup> James A Scott,<sup>2,3</sup> Ling Liu,<sup>4</sup> Raymond Poon,<sup>4</sup> Brent Coull,<sup>1</sup> Joel Schwartz,<sup>1</sup> Petros Koutrakis,<sup>1</sup> Frances Silverman,<sup>2,3,5,6,8</sup> Diane R Gold<sup>1,7</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/oemed-2013-101498>).

For numbered affiliations see end of article.

## Correspondence to

Dr Behrooz Behbod, Environmental Health, Harvard School of Public Health, 401 Park Drive West, Boston, MA 02215, USA; [bbehbod@post.harvard.edu](mailto:bbehbod@post.harvard.edu)

Received 10 March 2013

Revised 8 July 2013

Accepted 26 July 2013

Published Online First

16 August 2013

## ABSTRACT

**Background** Knowledge of the inhalable particulate matter components responsible for health effects is important for developing targeted regulation.

**Objectives** In a double-blind randomised cross-over trial of controlled human exposures to concentrated ambient particles (CAPs) and their endotoxin and (1→3)-β-D-glucan components, we evaluated acute inflammatory responses.

**Methods** 35 healthy adults were exposed to five 130-min exposures at rest: (1) fine CAPs (~250 μg/m<sup>3</sup>); (2) coarse CAPs (~200 μg/m<sup>3</sup>); (3) second coarse CAPs (~200 μg/m<sup>3</sup>); (4) filtered air; and (5) medical air. Induced sputum cell counts were measured at screening and 24 h postexposure. Venous blood total leucocytes, neutrophils, interleukin-6 and high-sensitivity C reactive protein (CRP) were measured pre-exposure, 3 and 24 h postexposure.

**Results** Relative to filtered air, an increase in blood leucocytes 24 h (but not 3 h) postexposure was significantly associated with coarse (estimate=0.44×10<sup>9</sup> cells/L (95% CI 0.01 to 0.88); n=132) and fine CAPs (0.68×10<sup>9</sup> cells/L (95% CI 0.19 to 1.17); n=132), but not medical air. Similar associations were found with neutrophil responses. An interquartile increase in endotoxin (5.4 ng/m<sup>3</sup>) was significantly associated with increased blood leucocytes 3 h postexposure (0.27×10<sup>9</sup> cells/L (95% CI 0.03 to 0.51); n=98) and 24 h postexposure (0.37×10<sup>9</sup> cells/L (95% CI 0.12 to 0.63); n=98). This endotoxin effect did not differ by particle size. There were no associations with glucan concentrations or interleukin-6, CRP or sputum responses.

**Conclusions** In healthy adults, controlled coarse and fine ambient particle exposures independently induced acute systemic inflammatory responses. Endotoxin contributes to the inflammatory role of particle air pollution.

## INTRODUCTION

It is well recognised that exposures to inhalable ambient particles are associated with significant morbidity and mortality.<sup>1–5</sup> Knowledge of the particulate matter (PM) components responsible for the health effects observed in epidemiological studies is of importance for the development of targeted air pollution regulations.

## What this paper adds

- In healthy adults, controlled coarse as well as fine ambient particle exposures independently induced acute systemic inflammatory responses.
- Endotoxin contributes to the inflammatory role of particle air pollution.
- Knowledge of the particulate matter components responsible for the health effects observed in epidemiological studies is of importance for the development of targeted air pollution regulations.

While fine (PM<sub>2.5</sub>) particles are being widely regulated, there is more uncertainty over the toxicity of coarse (PM<sub>2.5–10</sub>) particles.<sup>6</sup> Fine particles, derived mainly from mobile and industrial emission sources, are associated with cardiovascular outcomes and are able to reach the alveolar region and deposit mainly by interception.<sup>7</sup> Coarse particles have been shown to be associated with respiratory inflammation and disease as well as innate immune responses of airway macrophages,<sup>8</sup> and tend to deposit by inertial impaction in the extrathoracic airways (nose and pharynx; above the vocal cords).<sup>7</sup> Smaller coarse particles may also deposit onto the lower ciliated thoracic airways by gravitational sedimentation.<sup>9</sup>

Gram-negative bacterial cell walls contain endotoxin (lipopolysaccharide), which is composed of polysaccharide chains, a connecting core and a lipid A unit that is responsible for its toxic effects.<sup>10</sup> Another ambient biological exposure that is highly correlated with endotoxin levels is (1→3)-β-D-glucan (hereafter glucan). These compounds are glucose polymers that are non-allergenic water-insoluble structural cell wall components of most fungi, as well as some bacteria and plants. Their biological activity is independent of cell viability and may be potentiated by the degree of chemical branching and intermolecular association (ie, single/triple helix or randomly coil structures).<sup>11</sup>

Human controlled exposure studies<sup>12–15</sup> provide a unique opportunity to simulate air pollution levels like those seen regularly in cities like Beijing, China,<sup>16</sup> while allowing for experimental control

**To cite:** Behbod B, Urch B, Speck M, et al. *Occup Environ Med* 2013;**70**:761–767.

of the level of exposure. We used a double-blind randomised cross-over trial of controlled human exposures to coarse and fine concentrated ambient particles (CAPs) to evaluate their effects on acute pulmonary and secondary systemic inflammatory responses. In addition, we assessed whether exposure to increased concentrations of CAPs-associated endotoxin and glucan explained the inflammatory response to CAPs exposure.

## METHODS

### Study participants

We included 35 healthy non-smokers, aged 18–60 years, with no history of cardiovascular disease, hypertension (blood pressure >140/90 mm Hg) or diabetes. Subjects were not receiving treatment with cholesterol lowering medication or corticosteroids, and were free of respiratory tract infections for at least 3 weeks prior to exposure testing. Subjects were recruited from the University of Toronto Campus and surrounding area. The study was approved by the human research ethics committees of St. Michael's Hospital, the University of Toronto and Health Canada. All participants provided written informed consent before enrolling.

### Study design and exposure assessment

In a double-blind randomised cross-over block design, participants were exposed to five exposures: (1) fine CAPs between 0.1 and 2.5 microns aerodynamic diameter ( $\sim 250 \mu\text{g}/\text{m}^3$ ); (2) coarse CAPs between 2.5 and 10 microns aerodynamic diameter ( $\sim 200 \mu\text{g}/\text{m}^3$ ); (3) second coarse CAPs ( $\sim 200 \mu\text{g}/\text{m}^3$ ); (4) filtered air; and (5) medical air. Previous studies by our group had assessed the acute effects of fine CAPs.<sup>17 18</sup> When we began this study, the effects of coarse CAPs were not well assessed. We added the second coarse exposure per subject to increase the power to assess effects on outcomes. The two coarse exposures were handled as separate treatments in the statistical analyses to increase variability and power. Each exposure lasted 130 min (120-min exposure plus an additional 10 min to complete all test measures), followed by a minimum 2-week washout period before the next exposure. Controlled exposures were generated using high-flow (5000 L/min) Harvard ambient particle concentrators.<sup>19–21</sup> These particle concentration systems were used to draw ambient particles from a 1.8 m high PM<sub>10</sub> inlet located, 10 m from a busy 4-lane downtown Toronto street with  $\sim 2500$  vehicles passing during the 130-min exposure. Thus, traffic emissions were a major contributor to the ambient PM levels at this site. Ambient particle exposures were concentrated and adjusted through a dilution control system to deliver target concentrations of  $\sim 200 \mu\text{g}/\text{m}^3$  coarse CAPs and  $\sim 250 \mu\text{g}/\text{m}^3$  fine CAPs. The CAPs air stream was delivered directly to the subject seated inside a 4.9 m<sup>3</sup> Lexan and steel tube frame enclosure, at rest and breathing freely (no mouthpiece) via an 'oxygen type' face-mask covering his/her nose and mouth. The study design called for rest so there would be no interference with the cardiovascular measure of flow-mediated dilation (not included in this manuscript). The delivery system was designed so that there were no visual cues as to the exposure type while participants were seated in the chamber.

For filtered air exposures, the coarse concentrator was run with a high-efficiency particulate air (HEPA) filter placed inline to remove the particles. For medical air exposures, compressed breathing-grade medical air was humidified to 30% relative humidity, passed through an inline HEPA filter and delivered to the subject at a flow rate of 30 L/min. Medical air was selected because it is free of gaseous and particulate pollutants and odours.

The original study design (randomised block) only included the first four exposures (no medical air). However, interim analysis showed greater than expected physiological responses with filtered air, which was designed to serve as the control exposure and thus was expected to induce a negligible effect. We hypothesised that these responses may have been due to ambient gases such as volatile organic compounds that can pass through the HEPA filter. Thus, a fifth exposure using medical air was added as a second additional control, although in the first 11 subjects it was always delivered to the subject as the last exposure in the series (ie, not randomised), but then randomised in later subjects. This deviation from the randomised block design was considered in statistical analyses.

Endotoxin and glucan were both collected on polycarbonate membrane filters during coarse and fine CAPs and filtered air (but not medical air) exposures. Filters were placed in pyrogen-free 15 mL French square bottles containing 5 mL of Limulus Amebocyte Lysate reagent water. After shaking for 20 min and mixing for 1 min with a vortex, samples were divided into two aliquots of 2.5 mL. To measure endotoxin, the sample was sonicated for 30 min at 26°C and then vortexed for another 1 min. The extract was analysed for endotoxin using Pyrochrome and Glucashield reagents following manufacturer's instructions (Associates of Cape Cod, Inc. (ACC), East Falmouth, Massachusetts, USA). To measure glucan, 0.3 N NaOH was added to the sample, shaken on ice for 25 min and diluted with 10 mM NaOH. The extract was analysed for the amount of glucan using GlucateLL reagent (ACC).

### Outcome measures

We collected induced sputum at the screening visit (median 21 days prior to the first exposure treatment) and at 24 h postexposure. In this study, we used sputum total cell and neutrophil counts as outcomes. Venous blood was also collected from all study participants  $\sim 45$  min prior to, and 3 and 24 h after the start of each exposure. We evaluated total blood leucocyte and neutrophil counts as well as blood interleukin-6 (IL-6) and high-sensitivity C reactive protein (hs-CRP) as markers of inflammation.

### Statistical methods

We first described the baseline characteristics of the study participants and the exposure concentrations (mass, endotoxin and glucan) across the different treatments (coarse and fine CAPs and filtered/medical air). To account for the within-subject correlation in the outcome measures, while adjusting for daily physiological variability within subjects, we created new variables representing change. Therefore, blood outcomes were converted to: (1) 3 h post—pre change and (2) 24 h post—pre change. Sputum measures were converted to the 24 h postscreening visit change. However, since the screening visit was a median 21 days prior to the first exposure treatment, we also performed sensitivity analyses using 24 h post-sputum measures as a single measure. We assessed the outcome measure distributions for normality, and if skewed, we transformed the data, as appropriate, prior to further analyses.

We used linear mixed effects models to account for the within-subject correlation in responses between the exposure treatments. We first examined whether, relative to filtered air, coarse and fine CAPs and medical air exposures were independently associated with each outcome. We included the four exposure types (treatments) as a categorical variable, and used filtered air as the control, which was randomised for all subjects by design. We then examined whether, accounting for the exposure type, variations in bioaerosol (endotoxin, and glucan)

Table 1 Exposure characteristics

Exposure*	Total (all exposures)			Treatment type											
				Coarse CAPs (PM <sub>10-2.5</sub> )			Fine CAPs (PM <sub>2.5-0.1</sub> )			Filtered air			Medical air		
	N	Median	IQR	n	Median	IQR	n	Median	IQR	n	Median	IQR	n	Median	IQR
Particulate mass concentration (µg/m <sup>3</sup> )	132	189.6	220.3	55	202.3	35.8	29	234.7	52.4	25	-2.5	7.2	23	0.7	7.7
β-Glucan (ng/m <sup>3</sup> )	80	9.0	17.7	40	13.0	28.5	25	10.5	16.3	15	0.7	0.7	0		
Endotoxin (ng/m <sup>3</sup> )	98	4.8	5.4	51	5.4	2.9	28	7.1	7.1	19	0.4	1.0	0		

\*Integrated gravimetric (filter sample) 130-min exposure concentrations sampled from CAPs/filtered air airstream inlet to human chamber. CAPs, concentrated ambient particles; n, number of observations; PM, particulate matter.

concentrations were associated with the inflammatory outcomes. Due to the collinearity in bioaerosol concentrations, we assessed the effect of endotoxin and glucan in separate models. Coarse and fine CAPs-associated bioaerosols were initially grouped together. We subsequently used interaction terms between bioaerosol concentrations and CAPs size fraction to examine whether associations between bioaerosol exposures and outcomes were modified by CAPs size fraction.

All models were tested as follows: (1) unadjusted, assuming the randomised design efficiently accounted for measured and unmeasured confounders; (2) adjusting for exposure order (1st–5<sup>th</sup>, as in table 3), to account for any potential stress or cumulative responses; and (3) adjusting for subjects' age, gender, ethnicity, body mass index (BMI (kg/m<sup>2</sup>)) and season (categorical; four levels) of exposure treatment. Continuous covariates (age and BMI) were centred at their respective means. Last, sensitivity analyses were performed to ensure results were not due to any outliers, identified as the highest two/three exposure concentrations or outcomes (sputum/blood white cell and neutrophil counts).

## RESULTS

Overall, 19 (54%) men and 16 (46%) women completed a total of 132 controlled exposure treatments. In all, 17 (48%) were Asian, 16 (46%) were white and 2 (6%) were black. Their mean (IQR) age and BMI were 27 (11) years and 23 (3) kg/m<sup>2</sup>, respectively.

Table 1 shows the distribution of the 132 controlled exposure treatments. While the coarse and fine CAPs concentrations were tightly controlled by design, there was residual variability in both exposures ((IQR)<sub>coarse</sub>=35.8 µg/m<sup>3</sup>; (IQR)<sub>fine</sub>=52.4 µg/m<sup>3</sup>). Glucan levels obtained were on average (median (IQR)) 4.6 (5.2) times higher than ambient for coarse CAPs exposures, and 4.4 (2.2) for fine CAPs exposures. Endotoxin levels were on average (median (IQR)) 5.8 (4.2) times higher than ambient for coarse CAPs exposures, and 7.7 (3.9) for fine CAPs exposures. No particulate mass, glucan or endotoxin was found in the filtered air. We did not measure bioaerosol concentrations in medical air.

At baseline, all subjects were afebrile and showed no signs of infection (maximum total leucocyte counts=8.9×10<sup>9</sup> cells/L; maximum blood neutrophil counts=5.9×10<sup>9</sup> cells/L) or inflammation (maximum hs-CRP=6.9 µg/mL). With the exception of up to a few marked responses in each outcome, blood and sputum outcome distributions (table 2) were normally distributed. While the mean changes in blood and sputum outcomes appeared minimal, there was variability in the responses. However, we did not observe significant differences in subject characteristics (age, gender, ethnicity or BMI) between those with increased or decreased responses (results not shown).

Table 3 presents the associations between the controlled exposure treatments and the change in total blood leucocyte responses. While there appeared to be a response to filtered air (the reference group) 3 h postexposure in both the unadjusted model (intercept estimate=0.50×10<sup>9</sup> cells/L (95% CI 0.12 to 0.87)) and in model 1 adjusting for exposure order (estimate=0.62×10<sup>9</sup> cells/L (95% CI 0.20 to 1.05)), this was no longer statistically significant when we adjusted for potential confounders in model 2 (estimate=0.60×10<sup>9</sup> cells/L (95% CI -0.06 to 1.26)). Relative to filtered air, coarse and fine CAPs and medical air were not significantly associated with 3 h post-pre change blood leucocyte responses (model 2). However, an increase in total blood leucocytes 24 h postexposure (table 4, model 2) was significantly associated with coarse (estimate=0.44×10<sup>9</sup> cells/L (95% CI 0.01 to 0.88)) and fine CAPs (estimate=0.68×10<sup>9</sup> cells/L (95% CI 0.19 to 1.17)), but not medical air (estimate=0.36×10<sup>9</sup> cells/L (95% CI -0.20 to 0.93)). We performed sensitivity analyses by removing marked responses, and found consistent results in models with blood neutrophil responses (see online supplementary material table 1).

Adjusting for treatment type (table 3, model 4), an interquartile increase in endotoxin (5.4 ng/m<sup>3</sup>) was significantly associated (estimate=0.38×10<sup>9</sup> cells/L (95% CI 0.09 to 0.68)) with an increase in blood leucocytes 3 h postexposure. While an interquartile increase in endotoxin concentration was associated (estimate=0.37×10<sup>9</sup> cells/L (95% CI 0.12 to 0.63)) with higher leucocytes 24 h postexposure (table 4, model 3), this association was no longer significant when we adjusted for treatment type (table 4, model 4). In a model excluding medical air exposures to obtain the same number of observations as in model 4 (results not shown in tables), coarse (estimate=0.52×10<sup>9</sup> cells/L (95% CI 0.04 to 1.00)) and fine CAPs (estimate=0.74×10<sup>9</sup> cells/L (95% CI 0.21 to 1.27)) remained significantly associated with higher leucocyte levels 24 h postexposure. However, when including endotoxin in model 4, the associations of coarse and fine CAPs became non-significant and the respective effect estimates were reduced by 40% (0.52 to 0.31×10<sup>9</sup> cells/L) and 35% (0.74 to 0.48×10<sup>9</sup> cells/L). The association between increases in endotoxin concentration and leucocyte responses 3 h (p for interaction=0.67) or 24 h (p for interaction=0.42) postexposure did not vary significantly by CAPs size fraction.

Variations in glucan concentrations were not associated with 3 or 24 h postleucocyte responses. Relative to filtered air, fine CAPs exposures were associated (estimate=-0.62 µg/mL (95% CI -1.04 to -0.20), n=132) with lower hs-CRP responses 24 h post-treatment (see online supplementary material table 2). This negative association did not remain significant (estimate=-0.23 µg/mL (95% CI -0.62 to 0.15), n=128) after we removed four marked responses presented (-2.6, 1.4, 2.2 and

Table 2 Outcome characteristics

Outcome	N	Mean	Min	25th Percentile	50th	75th	Max	IQR
<i>Blood</i>								
Total leucocytes (# cells $\times 10^9$ /L)								
Pre-treatment	132	5.5	3.5	4.7	5.3	6.2	8.9	1.5
3 h post-treatment	132	5.8	3.5	5.0	5.6	6.5	10.0	1.5
24 h post-treatment	131	5.5	3.4	4.7	5.4	6.1	9.8	1.4
3 h post-pre change	132	0.4	-1.4	-0.3	0.4	0.9	5.0	1.2
24 h post-pre change	131	0.1	-2.7	-0.6	0.1	0.5	4.6	1.1
Neutrophils (# cells $\times 10^9$ /L)								
Pre-treatment	132	3.1	1.6	2.4	2.9	3.6	5.9	1.2
3 h post-treatment	132	3.5	1.6	2.6	3.2	4.0	8.4	1.4
24 h post-treatment	131	3.1	1.2	2.3	3.0	3.5	6.8	1.2
3 h post-pre change	132	0.4	-1.8	-0.1	0.2	0.7	5.7	0.8
24 h post-pre change	131	0.0	-2.7	-0.5	0.0	0.4	4.0	0.9
Interleukin-6 (pg/mL)								
Pre-treatment	121	1.0	0.0	0.5	0.7	1.1	5.2	0.6
3 h post-treatment	120	0.8	0.0	0.4	0.6	0.9	5.3	0.5
24 h post-treatment	121	1.1	0.0	0.5	0.8	1.1	6.0	0.6
3 h post-pre change	120	-0.1	-2.8	-0.3	-0.1	0.0	5.2	0.3
24 h post-pre change	121	0.1	-2.6	-0.2	0.0	0.2	4.9	0.4
hs-CRP ( $\mu$ g/mL)								
Pre-treatment	121	1.3	0.0	0.1	0.5	2.0	6.9	1.9
3 h post-treatment	120	1.2	0.0	0.1	0.4	1.9	7.1	1.8
24 h post-treatment	121	1.3	0.0	0.1	0.4	1.9	10.0	1.8
3 h post-pre change	120	0.0	-1.9	0.0	0.0	0.0	2.1	0.1
24 h post-pre change	121	0.1	-2.6	-0.1	0.0	0.1	4.2	0.2
<i>Induced sputum</i>								
Total cells (# cells $\times 10^5$ /mL)								
Screening visit	10	9.7	2.6	7.1	9.2	13.2	16.6	6.1
24 h post-treatment	38	10.8	3.2	7.4	10.0	12.7	40.6	5.3
24 h post-screening change	34	0.1	-10.2	-4.4	-0.7	5.0	19.1	9.4
Neutrophils (# cells $\times 10^5$ /mL)								
Screening visit	10	3.1	1.4	1.4	2.8	4.5	6.9	3.1
24 h post-treatment	38	4.4	0.1	1.0	2.7	6.6	17.9	5.6
24 h post-screening change	34	1.2	-4.1	-1.0	-0.1	2.5	13.6	3.5

hs-CRP, high sensitivity C reactive protein.

3.7  $\mu$ g/mL). We did not find any associations with blood IL-6 (see online supplementary material table 3) or sputum responses (see online supplementary material table 4).

## DISCUSSION

In a double-blind randomised cross-over trial in 35 healthy adult subjects, coarse and fine ambient particle exposures were independently associated with an acute inflammatory response. The endotoxin content partially explained the inflammatory role of ambient particle exposures, and the effect did not differ between coarse and fine particles.

While we observed significant associations with systemic inflammatory responses (blood neutrophils), the lack of significant corollary findings in sputum may be due to insufficient power because of the small sample size. Nevertheless, human exposure studies of CAPs have generally not shown consistent results with induced sputum, with suggestions that systemic inflammation may be more pronounced than pulmonary responses.<sup>22–25</sup> CAPs represent multiple sources of ambient pollutants rather than just diesel exhaust emissions. While we controlled total mass levels in our study, we were limited by not accounting for particle composition which varies with time due

to changes in source emissions and prevailing environmental conditions. CAP composition also varies by study location, and therefore our results from Toronto may not represent what might be found elsewhere.<sup>25</sup>

Ambient PM constituents may include chemicals such as metals, organics and biological materials from bacteria, viruses and fungi. An in vitro study of rat alveolar macrophage (AM) cells found that endotoxin in urban air particles, but not in diesel particles, was responsible for inducing inflammatory cytokine expression.<sup>26</sup> Humans may be more sensitive than animals to the effects of CAPs.<sup>22</sup> Becker *et al* (2005)<sup>27</sup> exposed AM cells from healthy adult subjects aged 20–35 years to fine and coarse particles in vitro and found that the main pro-inflammatory response was driven by the coarse size fraction, where the majority (~90%) of the stimulatory material in inhalable PM is known to be found.<sup>28</sup> This stimulatory material is mainly derived from biological sources, and includes microbes and allergens.

Alexis *et al* (2006)<sup>8</sup> exposed nine healthy subjects, on three separate occasions, to inhale nebulised saline (0.9%, control), coarse PM collected from local ambient air in Chapel Hill, North Carolina, USA that was heated (20 h at 120°C) to

**Table 3** Associations among 130-min controlled human exposure treatments, bioaerosols and 3-h changes in blood total leucocytes

Treatment (categorical)	3 h post—pre change in leucocytes (# cells×10 <sup>9</sup> /L)					
	Unadjusted (n=132)		Model 1 (n=132)		Model 2 (n=132)	
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Coarse CAPs	-0.10	(-0.46 to 0.26)	-0.12	(-0.49 to 0.25)	-0.12	(-0.50 to 0.26)
Fine CAPs	-0.04	(-0.44 to 0.37)	-0.07	(-0.49 to 0.35)	-0.06	(-0.49 to 0.36)
Medical air	-0.39	(-0.83 to 0.05)	-0.40	(-0.89 to 0.09)	-0.39	(-0.89 to 0.11)
Filtered air	Ref	Ref	Ref	Ref	Ref	Ref

  

Treatment (categorical)	Model 3 (n=98)		Model 4 (n=98)		Model 5 (n=80)		Model 6 (n=80)	
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Coarse CAPs	-	-	-0.25	(-0.72 to 0.23)	-	-	0.25	(-0.26 to 0.75)
Fine CAPs	-	-	-0.37	(-0.91 to 0.17)	-	-	0.27	(-0.24 to 0.78)
Medical air	-	-	-	-	-	-	-	-
Filtered air	-	-	Ref	Ref	-	-	Ref	Ref
Endotoxin† (ng/m <sup>3</sup> )	0.27*	(0.03 to 0.51)	0.38*	(0.09 to 0.68)	-	-	-	-
Glucan† (ng/m <sup>3</sup> )	-	-	-	-	0.10	(-0.06 to 0.25)	0.07	(-0.10 to 0.24)

Treatment group estimates are for the difference between filtered air and other treatment groups (coarse CAPs, fine CAPs or medical air) in leucocyte response (3 h postexposure minus pre-exposure) to the treatment.

Model 1 adjusts for exposure order (1st—5th).

Models 2–6 adjust for exposure order and subject characteristics: age (continuous), male gender, white ethnicity, BMI (continuous) and season (categorical; four levels).

Note: age and BMI are centred at the mean.

\*p≤0.05.

†Bioaerosol concentration (endotoxin or glucan) from coarse and fine CAPs. Estimates represent an interquartile increase in the exposure concentration (endotoxin=5.4 ng/m<sup>3</sup>; glucan=17.7 ng/m<sup>3</sup>).

BMI, body mass index; CAPs, concentrated ambient particles.

inactivate biological material, or non-heated PM. Relative to saline, coarse PM exposure was associated with an increase in inflammatory polymorphonuclear leucocytes and macrophage mRNA tumour necrosis factor (TNF)- $\alpha$ , an upregulation of immune surface phenotypes on macrophages (mCD14, CD11b, HLA-DR), and increased phagocytosis, 2–3 h postinhalation.

Biological inactivation was associated with lower mRNA TNF- $\alpha$ , phagocytosis and cell surface marker responses. Analysis of ambient coarse PM from Chapel Hill showed that it contained 30% gram-negative bacteria, with the remainder mostly composed of gram-positive cocci and fungal spores (*Penicillium*, *Cladosporium*).

**Table 4** Associations among 130-min controlled human exposure treatments, bioaerosols and 24-h changes in blood total leucocytes

Treatment (categorical)	24 h post—pre change in leucocytes (# cells×10 <sup>9</sup> /L)					
	Unadjusted (n=132)		Model 1 (n=132)		Model 2 (n=132)	
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Coarse CAP	0.35	(-0.10 to 0.80)	0.41	(-0.04 to 0.87)	0.44*	(0.01 to 0.88)
Fine CAP	0.67**	(0.16 to 1.17)	0.71**	(0.19 to 1.22)	0.68**	(0.19 to 1.17)
Medical air	0.21	(-0.33 to 0.74)	0.35	(-0.24 to 0.93)	0.36	(-0.20 to 0.93)
Filtered air	Ref	Ref	Ref	Ref	Ref	Ref

  

Treatment (categorical)	Model 3 (n=98)		Model 4 (n=98)		Model 5 (n=80)		Model 6 (n=80)	
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Coarse CAP	-	-	0.31	(-0.23, 0.85)	-	-	0.39	(-0.20, 0.98)
Fine CAP	-	-	0.48	(-0.14, 1.10)	-	-	0.75*	(0.15, 1.36)
Medical air	-	-	-	-	-	-	-	-
Filtered air	-	-	Ref	Ref	-	-	Ref	Ref
Endotoxin† (ng/m <sup>3</sup> )	0.37**	(0.12, 0.63)	0.25	(-0.05, 0.56)	-	-	-	-
Glucan† (ng/m <sup>3</sup> )	-	-	-	-	0.09	(-0.06, 0.25)	0.07	(-0.08, 0.22)

Treatment group estimates are for the difference between filtered air and other treatment groups (coarse CAPs, fine CAPs or medical air) in leucocyte response (24 h postexposure minus pre-exposure) to the treatment.

Model 1 adjusts for exposure order (1st—5th).

Models 2–6 adjust for exposure order and subject characteristics: age (continuous), male gender, white ethnicity, BMI (continuous) and season (categorical; four levels).

Note: age and BMI are centred at the mean.

\*p≤0.05, \*\*p≤0.01.

†Bioaerosol concentration (endotoxin or glucan) from coarse and fine CAPs. Estimates represent an interquartile increase in the exposure concentration (endotoxin=5.4 ng/m<sup>3</sup>; glucan=17.7 ng/m<sup>3</sup>).

BMI, body mass index; CAPs, concentrated ambient particles.

We measured slightly higher levels of endotoxin in fine than in coarse CAPs (table 1). This may be due to the fact that subjects were, by design, exposed to higher concentrations of fine ( $\sim 250 \mu\text{g}/\text{m}^3$ ) than coarse ( $\sim 200 \mu\text{g}/\text{m}^3$ ) CAPs. Nevertheless, a separate epigenetic analysis of our study found coarse CAPs exposure to be associated with lowered toll-like receptor (TLR)-4 methylation, which can recognise the endotoxin component of coarse CAPs and trigger macrophages to release various inflammatory cytokines.<sup>29</sup>

Concentrated ambient endotoxin concentrations, irrespective of CAPs size fraction, were over 17-fold greater (geometric mean  $\sim 34 \text{ EU}/\text{m}^3$ ) than levels normally found in outdoor and indoor air ( $< 2 \text{ EU}/\text{m}^3$ ).<sup>30–31</sup> Conversely, concentrated ambient glucan concentrations (geometric mean =  $8 \text{ ng}/\text{m}^3$ ) were just above levels found in total unconcentrated PM in normal indoor and outdoor air,<sup>24</sup> perhaps explaining why we did not find associations with glucan exposures in our study. Levels greater than  $5 \text{ ng}/\text{m}^3$  of glucan are generally associated with previous mould growth or water damage;<sup>32</sup> a villa with excessive mould growth had levels of up to  $100 \text{ ng}/\text{m}^3$ .<sup>33</sup> On the other hand, there may indeed be no health effects with glucan exposures.

A review of studies on the potential effects of glucan on airway inflammation showed mixed results.<sup>34</sup> This lack of consistency may be due to a number of reasons, such as small sample sizes, different exposure assessment methods, or lack of control for potential confounders or coexposures such as endotoxin.<sup>35–39</sup> Furthermore, health effects vary by route of exposure (eg, inhalation/oral) and type of glucan. The GlucateLL reagent used to measure glucan concentrations are specific to (1 $\rightarrow$ 3)- $\beta$ -D-glucan and, therefore, cross-reactivity with plant glucan that have 1 $\rightarrow$ 4 linkages (as found in barley) does not occur. However, factor G activation has a bias for higher molecular weight glucan and single-helix and randomly coiled conformers over triple-helix structures. The ELISA method has been shown to be specific for fungi, (1 $\rightarrow$ 6) side-branched and (1 $\rightarrow$ 3)- $\beta$ -D-glucan, as well as high molecular weight glucan, and may therefore be a better method for determining exposure to glucan likely to have important health effects.<sup>40</sup>

IL-6 is a cytokine that stimulates neutrophil production, the proliferation of B-lymphocytes and the production of acute phase proteins (APP) by the liver. CRP is an important APP that functions as a soluble pattern recognition receptor (PRR). PRRs, such as the family of TLRs, are found on antigen presenting cells and identify microbial conserved structures of pathogen-associated molecular patterns. The exposure duration (130 min) and length of follow-up (24 h) was sufficient to elicit changes in IL-6.<sup>20</sup> The lack of significant associations with IL-6 or CRP in this study may therefore be due to a number of other reasons, including: (1) healthy subjects may not be representative of the population susceptible to the inflammatory effects of CAPs exposure; (2) other cytokines may have been released by macrophages, such as IL-1, IL-8, TNF- $\alpha$  and platelet-activating factor; and (3) there may indeed have been no effects to detect.

Our study was limited by the short exposure durations and follow-up periods, which may not be completely representative of the spatiotemporal variability in real-life exposures. Due to collinearity of endotoxin and glucan exposures, we were unable to assess any effect measure modification of the association between endotoxin and inflammation by glucan. Furthermore, the selection of healthy adults may limit generalisability of study findings to susceptible subpopulation.<sup>6</sup> A limitation was that we did not evaluate differential deposition and we did not do nasal lavage (it would have been problematic to do both nasal lavage

and sputum evaluation). It is possible that the weak associations of coarse particles with sputum leucocytes counts relate, in part, to deposition patterns. Our primary endpoints in the main study from which our analyses came from were cardiovascular. Finally, we were limited in that we did not have the exposures prior to the chamber exposure. Due to the randomisation, the role of daily life exposures in the few days prior to each treatment were not expected to have had a differential impact on the association between exposures of varying size and health outcomes.

Despite these limitations, our study included a carefully standardised environment with well characterised exposures and physical activity levels. Our randomised study design enables subjects to serve as their own controls, thereby controlling for measured and unmeasured confounders. Circadian rhythms, physical activity and stress must be taken into account when analysing cytokines in peripheral blood; circadian rhythms were controlled for by standardising the time of day when exposure treatments were performed; subjects were seated at rest during treatments; and stress was accounted for by adjusting for exposure order in statistical analyses. Study team members and subjects were both unaware of their exposure assignment in this double-blind study, thereby preventing the introduction of bias.

## CONCLUSIONS

We have shown that short duration controlled human exposures to coarse and fine CAPs were independently associated with acute systemic inflammatory responses in healthy non-smoking adults. Endotoxin contributes to the inflammatory role of both coarse and fine particle air pollution.

## Author affiliations

<sup>1</sup>Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA

<sup>2</sup>Gage Occupational & Environmental Health Unit, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

<sup>3</sup>Division of Occupational and Environmental Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

<sup>4</sup>Health Canada, Ottawa, Ontario, Canada

<sup>5</sup>Southern Ontario Centre for Atmospheric Aerosol Research (SOCAAR), Toronto, Ontario, Canada

<sup>6</sup>Divisions of Occupational and Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

<sup>7</sup>The Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>8</sup>Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada

**Acknowledgements** The authors thank Jeffrey R Brook for support and advice in the setup and operation of the facility. This publication was made possible by the following grants: USEPA RD-83241601, RD-83479801, Health Canada, Environment Canada, AllerGen NCE, and NIH P01 ES009825. Its contents are solely the responsibility of the grantee and do not necessarily represent the official views of the USEPA. Further, USEPA does not endorse the purchase of any commercial products or services that might be mentioned in the publication. Dr Behbod's doctorate has been supported by the Harvard-Cyprus Endowment Scholarship.

**Contributors** BB is the primary author and performed all statistical analyses. BU, MS, JAS and FS were involved in the study design, data collection and analysis as well as write-up. LL, RP, BC, JS, PK and DRG were involved in study design, data analysis and write-up.

**Funding** Infrastructure for CAPs exposure facility provided by Southern Ontario Centre for Atmospheric Aerosol Research (SOCAAR) through funding from the Canada Foundation for Innovation (CFI).

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** St. Michael's Hospital, the University of Toronto and Health Canada.

**Provenance and peer review** Not commissioned; externally peer reviewed.

## REFERENCES

- 1 Dockery DW, Pope A, Xu X, *et al.* An association between air pollution and mortality in six U.S. cities. *N Engl J Med* 1993;29:1753–9.
- 2 Pope CA III, Thun MJ, Namboodiri MM, *et al.* Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. *Am J Respir Crit Care Med* 1995;151:669–74.
- 3 Pope CA, Dockery DW. Epidemiology of particle effects. In: Holgate ST Jr, Samet JM Jr, Koren HS Jr, Maynard RL Jr, eds. *Air Pollution and Health*. London: Academic Press, 1998;673–705.
- 4 Samet JM, Zeger SL, Dominici F, *et al.* The National Morbidity, Mortality, and Air Pollution Study. Part II: Morbidity and mortality from air pollution in the United States. *Res Rep Health Eff Inst* 2000;94:5–70; discussion 71–79.
- 5 Schwartz J, Dockery DW, Neas LM. Is daily mortality associated specifically with fine particles? *J Air Waste Manag Assoc* 1996;46:927–39.
- 6 U.S. EPA. Integrated Science Assessment for Particulate Matter (Final Report). U.S. Environmental Protection Agency, Washington, DC, EPA/600/R-08/139F, 2009.
- 7 Heyder J, Gebhart J, Rudolf G, *et al.* Deposition of particles in the human respiratory tract in the size range 0.005–15µm. *J Aerosol Sci* 1986;17: 811–25.
- 8 Alexis NE, Lay JC, Zeman K, *et al.* Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers. *J Allergy Clin Immunol* 2006;117:1396–403.
- 9 Hinds WC. *Aerosol Technology: Properties, behavior, and measurement of airborne particles*. 2nd ed. New York: John Wiley & Sons, 1999:237.
- 10 Rylander R. Review: Endotoxin in the environment — exposure and effects. *J Endotoxin Research* 2002;8:241.
- 11 Young SH, Robinson V, Barger M, *et al.* Exposure to particulate (1→3)-β-D-glucans induces greater pulmonary toxicity than soluble (1→3)-β-D-glucans in rats. *J Toxicol Environ Health* 2003;66:25–38.
- 12 Ghio AJ, Hall A, Bassett MA, *et al.* Exposure to concentrated ambient air particles alters hematologic indices in humans. *Inhal Toxicol* 2003;15:1465–78.
- 13 Gong H, Linn WS, Terrell SL, *et al.* Exposures of elderly volunteers with and without chronic obstructive pulmonary disease (COPD) to concentrated ambient fine particulate pollution. *Inhal Toxicol* 2004;16:731–44.
- 14 Harder SD, Soukup JM, Ghio AJ, *et al.* Inhalation of PM2.5 does not modulate host defense or immune parameters in blood or lung of normal human subjects. *Environ Health Perspect* 2001;109(Suppl 4):599–604.
- 15 Samet JM, Graff D, Berntsen J, *et al.* A comparison of studies on the effects of controlled exposure to fine, coarse and ultrafine ambient particulate matter from a single location. *Inhal Toxicol* 2007;19(Suppl 1):29–32.
- 16 Streets DG, Fu JS, Jang CJ, *et al.* Air quality during the 2008 Beijing Olympic Games. *Atmospheric Environment* 2007;41:480–92.
- 17 Urch B, Brook JR, Wasserstein D, *et al.* Relative contributions of PM2.5 chemical constituents to acute arterial vasoconstriction in humans. *Inhal Toxicol* 2004;16:345–52.
- 18 Urch B, Silverman F, Corey P, *et al.* Acute blood pressure responses in healthy adults during controlled air pollution exposures. *Environ Health Perspect* 2005;113:1052–5.
- 19 Demokritou P, Gupta T, Ferguson S, *et al.* Development and laboratory characterization of a prototype coarse particle concentrator for inhalation toxicological studies. *Aerosol Science* 2002;33:1111–23.
- 20 Rastogi N, McWhinney RD, Akhtar US, *et al.* Physical Characterization of the University of Toronto Coarse, Fine, and Ultrafine High-Volume Particle Concentrator Systems. *Aerosol Sci Technol* 2012;46:1015–24.
- 21 Sioutas C, Koutrakis P, Godleski JJ, *et al.* Fine particle concentrators for inhalation exposures—Effect of particle size and composition. *J Aerosol Sci* 1997;28:1057–71.
- 22 Ghio AJ, Kim C, Devlin RB. Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers. *Am J Respir Crit Care Med* 2000;162(Suppl. 3 Pt 1):981–8.
- 23 Gong H Jr, Sioutas C, Linn WS. Controlled exposures of healthy and asthmatic volunteers to concentrated ambient PM10 and PM2.5 in Reno, NV. In: Mathal CV, Stonefield DH. eds. *Transactions, PM-10: Implementation of Standards*. Pittsburgh, PA: Air and Waste Management Association, 1988:437–9.
- 24 Urch B, Speck M, Corey P, *et al.* Concentrated ambient fine particles and not ozone induce a systemic interleukin-6 response in humans. *Inhalation Toxicology* 2010;22:210–18.
- 25 Holgate ST, Devlin RB, Wilson SJ, *et al.* Health effects of acute exposure to air pollution. Part II: Healthy subjects exposed to concentrated ambient particles. *Res Rep Health Eff Inst* 2003;112:31–50; discussion 51–67.
- 26 Dong W, Lewtas J, Luster MI. Role of Endotoxin in Tumor Necrosis Factor α Expression from Alveolar Macrophages Treated with Urban Air Particles. *Exp Lung Res* 1996;22:577–92.
- 27 Becker S, Mundandhara S, Devlin RB, *et al.* Regulation of cytokine production in human alveolar macrophages and airway epithelial cells in response to ambient air pollution particles: Further mechanistic studies. *Toxicol Appl Pharmacol* 2005;207: S269–75.
- 28 Soukup JM, Becker S. Human alveolar macrophage responses to air pollution particulates are associated with insoluble components of coarse material, including particulate endotoxin. *Toxicol Appl Pharmacol* 2001;171:20–6.
- 29 Bellavia A, Urch B, Speck M, *et al.* DNA hypomethylation, ambient particulate matter, and increased blood pressure: findings from controlled human exposure experiments. *J Am Heart Assoc* 2013;2:e000212.
- 30 Jacobs RR. Endotoxins in the environment. *Int J Occup Environ Health* 1997;3: S3–5.
- 31 Park JH, Spiegelman DL, Gold DR, *et al.* Predictors of Airborne Endotoxin in the Home. *Environ Health Perspect* 2001;109:859–64.
- 32 Thorn J, Rylander R. Airways Inflammation and Glucan in a Rowhouse Area. *Am J Respir Crit Care Med* 1998;157:1798–803.
- 33 Rylander R. The first case of sick building syndrome in Switzerland. *Indoor Environ* 1994;3:159–62.
- 34 Douwes J. (1→3)-β-D-glucans and respiratory health: a review of the scientific evidence. *Indoor Air* 2005;15:160–9.
- 35 Bowers GJ, Patchen ML, Macvittie TJ, *et al.* A comparative evaluation of particulate and soluble glucan in an endotoxin model. *Int J Immunopharmacol* 1986;8:313–21.
- 36 Cook JA, Dougherty WJ, Holt TM. Enhanced sensitivity to endotoxin induced by the RE stimulant, glucan. *Circ Shock* 1980;7:225–38.
- 37 Fogelmark B, Goto J, Yuasa K, *et al.* Acute pulmonary toxicity of inhaled (1→3)-β-D-glucan and endotoxin. *Agents Actions* 1992;35:50–5.
- 38 Fogelmark B, Sjöstrand M, Rylander R. Pulmonary inflammation induced by repeated inhalations of beta(1,3)-D-glucan and endotoxin. *Int J Exp Pathol* 1994;75:85–90.
- 39 Young SH, Robinson VA, Barger M, *et al.* Modified endotoxin responses in rats pretreated with 1–3-beta-glucan (zymosan A). *Toxicol Appl Pharmacol* 2002;178:172–9.
- 40 Milton DK, Alwis KU, Fiset L, *et al.* Enzyme-Linked Immunosorbent Assay Specific for (1→6) Branched, (1→3)-β-D-Glucan Detection in Environmental Samples. *Appl Environ Microbiol* 2001;67:5420–4.



## Endotoxin in concentrated coarse and fine ambient particles induces acute systemic inflammation in controlled human exposures

Behrooz Behbod, Bruce Urch, Mary Speck, James A Scott, Ling Liu, Raymond Poon, Brent Coull, Joel Schwartz, Petros Koutrakis, Frances Silverman and Diane R Gold

*Occup Environ Med* 2013 70: 761-767 originally published online August 16, 2013

doi: 10.1136/oemed-2013-101498

---

Updated information and services can be found at:  
<http://oem.bmj.com/content/70/11/761>

---

*These include:*

### Supplementary Material

Supplementary material can be found at:  
<http://oem.bmj.com/content/suppl/2013/08/16/oemed-2013-101498.DC1.html>

### References

This article cites 36 articles, 2 of which you can access for free at:  
<http://oem.bmj.com/content/70/11/761#BIBL>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Topic Collections

Articles on similar topics can be found in the following collections

[Air pollution, air quality](#) (180)  
[Other exposures](#) (838)

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>